PL1633726T3 - Pochodne pirymidyny użyteczne w leczeniu chorób w których pośredniczy CRTH2 - Google Patents

Pochodne pirymidyny użyteczne w leczeniu chorób w których pośredniczy CRTH2

Info

Publication number
PL1633726T3
PL1633726T3 PL04727274T PL04727274T PL1633726T3 PL 1633726 T3 PL1633726 T3 PL 1633726T3 PL 04727274 T PL04727274 T PL 04727274T PL 04727274 T PL04727274 T PL 04727274T PL 1633726 T3 PL1633726 T3 PL 1633726T3
Authority
PL
Poland
Prior art keywords
crth2
treatment
pyrimidine derivatives
diseases mediated
derivatives useful
Prior art date
Application number
PL04727274T
Other languages
English (en)
Inventor
Tai-Wei Ly
Yuji Koriyama
Takashi Yoshino
Hiroki Sato
Kazuho Tanaka
Hiromi Sugimoto
Yoshihisa Manabe
Kevin Bacon
Klaus Urbahns
Masanori Seki
Takuya Shintani
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Publication of PL1633726T3 publication Critical patent/PL1633726T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL04727274T 2003-04-25 2004-04-14 Pochodne pirymidyny użyteczne w leczeniu chorób w których pośredniczy CRTH2 PL1633726T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03009384A EP1471057B1 (en) 2003-04-25 2003-04-25 Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2
PCT/EP2004/003910 WO2004096777A1 (en) 2003-04-25 2004-04-14 Pyrimidine derivatives useful for the treatment of diseases mediated by crth2
EP04727274A EP1633726B1 (en) 2003-04-25 2004-04-14 Pyrimidine derivatives useful for the treatment of diseases mediated by crth2

Publications (1)

Publication Number Publication Date
PL1633726T3 true PL1633726T3 (pl) 2011-06-30

Family

ID=32946880

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04727274T PL1633726T3 (pl) 2003-04-25 2004-04-14 Pochodne pirymidyny użyteczne w leczeniu chorób w których pośredniczy CRTH2

Country Status (32)

Country Link
US (2) US7812160B2 (pl)
EP (2) EP1471057B1 (pl)
JP (2) JP4671955B2 (pl)
KR (1) KR101110491B1 (pl)
CN (2) CN1809539B (pl)
AR (1) AR043885A1 (pl)
AT (2) ATE316077T1 (pl)
AU (1) AU2004233966B2 (pl)
BR (1) BRPI0409733A (pl)
CA (1) CA2523439C (pl)
CL (1) CL43596B (pl)
CY (1) CY1111295T1 (pl)
DE (2) DE60303238T2 (pl)
DK (2) DK1471057T3 (pl)
DO (1) DOP2004000875A (pl)
ES (2) ES2257616T3 (pl)
GT (1) GT200400079A (pl)
HN (1) HN2004000129A (pl)
IL (1) IL171566A (pl)
MX (1) MXPA05011399A (pl)
MY (1) MY147984A (pl)
NO (1) NO20055588L (pl)
NZ (1) NZ543693A (pl)
PE (1) PE20050143A1 (pl)
PL (1) PL1633726T3 (pl)
PT (2) PT1471057E (pl)
RU (1) RU2361865C2 (pl)
SI (1) SI1633726T1 (pl)
TW (1) TWI353980B (pl)
UY (1) UY28286A1 (pl)
WO (1) WO2004096777A1 (pl)
ZA (1) ZA200508722B (pl)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
PT1471057E (pt) 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
PL3718564T3 (pl) * 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
CN100584844C (zh) 2004-01-31 2010-01-27 艾克提麦斯医药品有限公司 咪唑[1,2-c]嘧啶基乙酸衍生物
US7714132B2 (en) 2004-03-11 2010-05-11 Actelion Pharmaceuticals, Ltd. Tetrahydropyridoindole derivatives
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
UY29223A1 (es) 2004-11-23 2006-06-30 Astrazeneca Ab Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
ZA200709817B (en) 2005-04-21 2009-02-25 Serono Lab 2,3 substituted pyrazine sulfonmides as inhibitors of CRTH2
PL1891075T3 (pl) 2005-05-24 2011-12-30 Merck Serono Sa Spiropochodne tricykliczne jako modulatory CRTH2
DOP2006000210A (es) * 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
EP1937632A1 (en) 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds
WO2007062677A1 (en) * 2005-11-30 2007-06-07 7Tm Pharma A/S Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands
AU2007256597A1 (en) * 2006-06-09 2007-12-13 Icos Corporation Substituted phenyl acetic acids as DP-2 antagonists
EP2132196A1 (en) 2007-02-26 2009-12-16 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
US8507005B2 (en) * 2007-06-21 2013-08-13 Actimis Pharmaceuticals, Inc. Particulates of a CRTH2 antagonist
EP2176240A1 (en) * 2007-06-21 2010-04-21 Actimis Pharmaceuticals, Inc., Amine salts of a crth2 antagonist
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
BRPI0817318A2 (pt) * 2007-09-25 2015-03-17 Actimis Pharmaceuticals Inc Composto, composição farmacêutica, e, método para tratar uma doença, ou uma condição, ou sintoma da mesma.
JP5524847B2 (ja) * 2007-09-25 2014-06-18 アクチミス ファーマシューティカルズ インコーポレーテッド Ｃｒｔｈ２アンタゴニストとしてのアルキルチオピリミジン
BRPI0907364A2 (pt) 2008-02-01 2015-07-14 Amira Pharmaceuticals Inc Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
WO2009102893A2 (en) 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
JP2011513242A (ja) 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US8071807B2 (en) 2008-07-03 2011-12-06 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
US8541419B2 (en) 2008-09-02 2013-09-24 Actimis Pharmaceuticals, Inc. Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
SG172383A1 (en) * 2008-12-25 2011-07-28 Taisho Pharmaceutical Co Ltd Isoquinoline derivative
EP2393492A1 (en) * 2009-02-09 2011-12-14 Boehringer Ingelheim International GmbH New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
CA2751260A1 (en) 2009-02-12 2010-08-19 Stefano Crosignani Phenoxy acetic acid derivatives
WO2010094643A1 (en) * 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
EP2461809A4 (en) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
GB0913636D0 (en) * 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
US8815917B2 (en) 2009-08-05 2014-08-26 Panmira Pharmaceuticals, Llc DP2 antagonist and uses thereof
EA201200765A1 (ru) * 2009-11-24 2013-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения полиморфной модификации холиновой соли производного пиримидин-5-илуксусной кислоты
EP2521713A4 (en) 2010-01-06 2013-10-02 Panmira Pharmaceuticals Llc ANTAGONIST OF DP2 AND ITS USES
GEP20146177B (en) 2010-01-27 2014-10-10 Boehringer Ingelheim Int Pyrazole compounds as crth2 antagonists
MX2012014667A (es) 2010-06-23 2013-02-15 Taisho Pharma Co Ltd Derivado de isoquinolina.
CN102958914B (zh) 2010-07-05 2015-05-27 埃科特莱茵药品有限公司 1-苯基取代的杂环衍生物及其作为前列腺素d2受体调节剂的用途
JP2013535456A (ja) 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
JP2013535457A (ja) 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
MX346116B (es) 2010-10-20 2017-03-08 Valspar Sourcing Inc Sistema de revestimiento a base de agua con adhesion mejorada a una amplia variedad de sustratos revestidos y sin revestir, incluido el acero inoxidable de grado silenciador.
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US8759386B2 (en) 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
JP5999387B2 (ja) 2011-03-25 2016-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｒｔｈ２拮抗薬としてのピラゾール化合物
JP5988253B2 (ja) 2011-05-16 2016-09-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ［４，６−ビス−ジメチルアミノ−２−［４−（４−トリフルオロメチルベンゾイル−アミノ）ベンジル］ピリミジン−５−イル］酢酸の調製方法
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
TW201331179A (zh) 2011-12-21 2013-08-01 Actelion Pharmaceuticals Ltd 雜環衍生物及其作為前列腺素ｄ２受體調節劑之用途
CA2876808A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
WO2014079806A1 (en) 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrimidine compounds for treating hairloss
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体
GB9125842D0 (en) * 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
KR20000068354A (ko) * 1996-09-06 2000-11-25 다께다 가즈히꼬 신규 아세트아미드 유도체 및 프로테아제 저해제
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
HUP0301932A3 (en) * 2000-05-22 2007-09-28 Leo Pharma As Benzophenones as inhibitors of il-1 beta and tnf-alpha, pharmaceutical compositions containing them and use of them for producing pharmaceutical compositions
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1413306A1 (en) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
PL377314A1 (pl) 2002-12-20 2006-01-23 Amgen Inc. Modulatory astmy i zapaleń na tle alergicznym
PT1471057E (pt) * 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
EP2176240A1 (en) 2007-06-21 2010-04-21 Actimis Pharmaceuticals, Inc., Amine salts of a crth2 antagonist
US8507005B2 (en) 2007-06-21 2013-08-13 Actimis Pharmaceuticals, Inc. Particulates of a CRTH2 antagonist

Also Published As

Publication number Publication date
KR101110491B1 (ko) 2012-01-31
DOP2004000875A (es) 2004-10-31
NO20055588D0 (no) 2005-11-25
PT1633726E (pt) 2011-02-22
PE20050143A1 (es) 2005-04-01
GT200400079A (es) 2004-11-30
AU2004233966A1 (en) 2004-11-11
JP5161290B2 (ja) 2013-03-13
WO2004096777A1 (en) 2004-11-11
EP1471057A1 (en) 2004-10-27
ES2358424T3 (es) 2011-05-10
US7812160B2 (en) 2010-10-12
PT1471057E (pt) 2006-05-31
JP2006524645A (ja) 2006-11-02
BRPI0409733A (pt) 2006-05-09
NZ543693A (en) 2009-05-31
DK1633726T3 (da) 2011-03-28
TWI353980B (en) 2011-12-11
EP1471057B1 (en) 2006-01-18
NO20055588L (no) 2006-01-24
CY1111295T1 (el) 2015-08-05
AU2004233966B2 (en) 2010-11-11
US20070129355A1 (en) 2007-06-07
DE602004030907D1 (de) 2011-02-17
CN1809539B (zh) 2012-05-09
TW200505873A (en) 2005-02-16
DE60303238D1 (de) 2006-04-06
ATE494279T1 (de) 2011-01-15
MY147984A (en) 2013-02-28
KR20060089622A (ko) 2006-08-09
RU2005136655A (ru) 2006-06-10
CA2523439C (en) 2012-06-19
SI1633726T1 (sl) 2011-04-29
HN2004000129A (es) 2009-05-14
HK1095320A1 (en) 2007-05-04
US20100322980A1 (en) 2010-12-23
RU2361865C2 (ru) 2009-07-20
JP4671955B2 (ja) 2011-04-20
EP1633726B1 (en) 2011-01-05
ZA200508722B (en) 2006-12-27
CN1809539A (zh) 2006-07-26
CA2523439A1 (en) 2004-11-11
US7960393B2 (en) 2011-06-14
DK1471057T3 (da) 2006-05-15
DE60303238T2 (de) 2006-09-14
JP2011068657A (ja) 2011-04-07
CL43596B (es) 2005-03-18
IL171566A (en) 2011-03-31
CN101914065A (zh) 2010-12-15
MXPA05011399A (es) 2006-05-31
AR043885A1 (es) 2005-08-17
EP1633726A1 (en) 2006-03-15
ES2257616T3 (es) 2006-08-01
ATE316077T1 (de) 2006-02-15
UY28286A1 (es) 2004-11-30

Similar Documents

Publication Publication Date Title
PL1633726T3 (pl) Pochodne pirymidyny użyteczne w leczeniu chorób w których pośredniczy CRTH2
GB0312832D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
AP2005003283A0 (en) Indole derivatives useful for the treatment os diseases
IL189657A (en) Process for the preparation of n-phenyl-2-pyrimidine-amine derivatives
IL172346A0 (en) Treatment of t cell mediated diseases by inhibition of fgfr3
AU2003285091A1 (en) Interferon antagonists useful for the treatment of interferon related diseases
IL176629A0 (en) Sulfonamide derivatives for the treatment of diseases
AP2006003669A0 (en) Sulfonamide derivatives for the treatment of diseases
PL1685125T3 (pl) Pochodne pirrolowe użyteczne do leczenia chorób proliferacyjnych
GB0329874D0 (en) Compounds useful for the treatment of diseases
PL377164A1 (pl) Pochodne anilinopirazolu przydatne do leczenia cukrzycy
PT1487828E (pt) Derivados de morfolinil-ureia para utilização no tratamento de doenças inflamatórias
IL177455A0 (en) Pyrazoline derivatives useful for the treatment of cancer
IL166226A0 (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-HT2A receptor-related disorders
GB0201025D0 (en) The treatment of degenerative diseases
IL172377A0 (en) 2-ethoxy-3-phenylpropionic acid derivatives for the treatment of lipid disorders
AU2003232844A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
GB0312842D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
GB0312840D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
GB0425054D0 (en) Formamide derivatives for the treatment of diseases
ZA200606780B (en) Compounds for the treatment of diseases
GB0217205D0 (en) 2-Amino-pyridine derivatives useful for the treatment of diseases
GB0326967D0 (en) Use of pyrimidine derivatives for the treatment of psychiatric disorders
SI1534391T1 (sl) Novi piperazinil-pirazinonski derivati za zdravljenje motenj, povezanih z receptorjem 5-HT2A